BioCentury
ARTICLE | Deals

Gritstone seeks value in infectious diseases through Gilead deal, but isn’t leaving neoantigens behind

February 2, 2021 2:30 AM UTC

While neoantigen cancer vaccines have yet to meet high investor expectations, Gritstone is uncovering new value for its neoantigen platform in infectious diseases, most recently through a partnership with Gilead to develop HIV vaccines. 

On Monday, Gritstone Oncology Inc. (NASDAQ:GRTS) and Gilead Sciences Inc. (NASDAQ:GILD) announced a new collaboration to develop curative HIV vaccines by combining Gritstone’s vaccine platform with Gilead’s antigens and deep HIV expertise. ...